-
EP1268799
European procedure
Extract from the Register of European Patents
EP About this file: EP1268799
| EP1268799 - ANTAGONIST ANTIBODIES TO VE-CADHERIN WITHOUT ADVERSE EFFECTS ON VASCULAR PERMEABILITY [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 15.01.2010 Database last updated on 14.11.2024 | Most recent event Tooltip | 15.01.2010 | No opposition filed within time limit | published on 17.02.2010 [2010/07] | Applicant(s) | For all designated states IMCLONE SYSTEMS, INC. 180 Varick Street New York, NY 10014 / US | [2003/01] | Inventor(s) | 01 /
LIAO, Fang 500 East 63rd Street New York, NY 10021 / US | 02 /
HICKLIN, Daniel, J. 169 Stonehouse Road GlenRidge, NJ 07028 / US | 03 /
BOHLEN, Peter 178 East 80th Street New York, NY 10021 / US | [2003/01] | Representative(s) | Banford, Paul Clifford, et al Marks & Clerk LLP 1 New York Street Manchester, M1 4HD / GB | [N/P] |
| Former [2008/34] | Banford, Paul Clifford, et al Marks & Clerk Sussex House 83-85 Mosley Street Manchester M2 3LG / GB | ||
| Former [2003/01] | Beetz & Partner Patentanwälte Steinsdorfstrasse 10 80538 München / DE | Application number, filing date | 01922997.0 | 30.03.2001 | [2003/01] | WO2001US10505 | Priority number, date | US20000540967 | 31.03.2000 Original published format: US 540967 | [2003/01] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO0175109 | Date: | 11.10.2001 | Language: | EN | [2001/41] | Type: | A2 Application without search report | No.: | EP1268799 | Date: | 02.01.2003 | Language: | EN | The application published by WIPO in one of the EPO official languages on 11.10.2001 takes the place of the publication of the European patent application. | [2003/01] | Type: | B1 Patent specification | No.: | EP1268799 | Date: | 11.03.2009 | Language: | EN | [2009/11] | Search report(s) | International search report - published on: | EP | 16.05.2002 | Classification | IPC: | C12N15/13, C07K16/28, C12N5/20, A61K39/395, A61P35/00, A61P37/00, A61P9/00, A61P27/00, A61P19/02, C12N15/63, A61K48/00 | [2003/01] | CPC: |
C07K16/2896 (EP,US);
A61P19/02 (EP);
A61P27/00 (EP);
A61P27/02 (EP);
A61P27/06 (EP);
A61P35/00 (EP);
A61P35/02 (EP);
A61P35/04 (EP);
A61P37/00 (EP);
A61P9/00 (EP);
A61K2039/505 (EP,US);
A61K48/00 (EP,US);
C07K2317/34 (EP,US)
(-)
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2003/01] | Extension states | AL | Not yet paid | LT | Not yet paid | LV | Not yet paid | MK | Not yet paid | RO | Not yet paid | SI | Not yet paid | Title | German: | ANTAGONISTISCHE ANTIKÖRPER GEGEN VE-CADHERIN OHNE NEGATIVE EFFEKTE AUF DIE VASKULÄRE PERMEABILITÄT | [2003/01] | English: | ANTAGONIST ANTIBODIES TO VE-CADHERIN WITHOUT ADVERSE EFFECTS ON VASCULAR PERMEABILITY | [2003/01] | French: | ANTAGONISTES D'ANTICORPS DE LA VE-CADHERINE N'AYANT PAS D'EFFETS DEFAVORABLES SUR LA PERMEABILITE VASCULAIRE | [2003/01] | Entry into regional phase | 23.10.2002 | National basic fee paid | 23.10.2002 | Designation fee(s) paid | 23.10.2002 | Examination fee paid | Examination procedure | 24.10.2001 | Request for preliminary examination filed International Preliminary Examining Authority: US | 23.10.2002 | Examination requested [2003/01] | 18.08.2005 | Despatch of a communication from the examining division (Time limit: M06) | 20.03.2006 | Reply to a communication from the examining division | 18.04.2006 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 23.10.2006 | Despatch of a communication from the examining division (Time limit: M06) | 02.05.2007 | Reply to a communication from the examining division | 19.09.2007 | Despatch of a communication from the examining division (Time limit: M04) | 29.01.2008 | Reply to a communication from the examining division | 28.08.2008 | Cancellation of oral proceeding that was planned for 26.09.2008 | 28.08.2008 | Minutes of oral proceedings despatched | 26.09.2008 | Date of oral proceedings | 26.09.2008 | Date of oral proceedings (cancelled) | 06.10.2008 | Communication of intention to grant the patent | 06.01.2009 | Fee for grant paid | 06.01.2009 | Fee for publishing/printing paid | Opposition(s) | 14.12.2009 | No opposition filed within time limit [2010/07] | Request for further processing for: | 28.06.2006 | Request for further processing filed | 28.06.2006 | Full payment received (date of receipt of payment) Request granted | 14.07.2006 | Decision despatched | Fees paid | Renewal fee | 24.03.2003 | Renewal fee patent year 03 | 22.03.2004 | Renewal fee patent year 04 | 22.03.2005 | Renewal fee patent year 05 | 29.03.2006 | Renewal fee patent year 06 | 28.03.2007 | Renewal fee patent year 07 | 27.03.2008 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]US5597725 (SUZUKI SHINTARO [US]) [A] 1-22 * example 4 * * table 2 * * seq.id.no. 50 *; | [A] - F. LIAO ET AL., "Identification of antibody-based VE-cadherin antagonists for the application of anti-angiogenesis therapy.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., Baltimore, MD, USA, (200003), vol. 41, page 645, XP002187984 [A] 1-19 * abstract #4096 * | [DA] - F. BREVIARIO ET AL., "Functional properties of human vascular endothelial cadherin (7B4/cadherin-5), and endothelium-specific cadherin.", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, Dallas, TX, USA, (199508), vol. 15, no. 8, pages 1229 - 1239, XP000576820 [DA] 1-22 * Methods. Antibodies and recombinant fragments * * figure 1 * | [DA] - T. BACH ET AL., "VE-cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels.", EXPERIMENTAL CELL RESEARCH, New York, NY, USA, (19980201), vol. 238, no. 2, pages 324 - 334, XP001024138 [DA] 1-22 * abstract * * page 325, column R, line 24 - line 26 * * page 332, column L, line 40 - line 50 * DOI: http://dx.doi.org/10.1006/excr.1997.3844 | [A] - F. HASELTON ET AL., "Role of cadherins 5 and 13 in the aortic endothelial barrier.", JOURNAL OF CELLULAR PHYSIOLOGY, Philadelphia, PA, USA, (199706), vol. 171, no. 3, pages 243 - 251, XP001024203 [A] 1-22 * abstract * DOI: http://dx.doi.org/10.1002/(SICI)1097-4652(199706)171:3<243::AID-JCP2>3.0.CO;2-O | [PA] - M. CORADA ET AL., "Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability.", BLOOD, New York, NY, USA, (20010315), vol. 97, no. 6, pages 1679 - 1684, XP002187985 [PA] 1-22 * the whole document * DOI: http://dx.doi.org/10.1182/blood.V97.6.1679 |